Immune System Key Ltd.
  • Home
  • News & Events
  • Science And R&D
    • Nerofe Pipeline
    • Technology
    • Nerofe Mode of Action
    • Phase I Results
    • First Success Story
  • Company Description
    • Team
  • Contact Us
Immune System Key Ltd.
  • Home
  • News & Events
  • Science And R&D
    • Nerofe Pipeline
    • Technology
    • Nerofe Mode of Action
    • Phase I Results
    • First Success Story
  • Company Description
    • Team
  • Contact Us

ISK received the FDA’s approval to start Phase 1b/2a with AML patients

  • Home
  • News
  • ISK received the FDA’s approval to start Phase 1b/2a with AML patients

ISK received the FDA’s approval to start Phase 1b/2a with AML patients

09/01/2020
Joel Ohana2020-01-15T14:27:25+02:0009 Jan|

Related Posts

  • Second FDA approved clinical trial in patients with pancreatic cancer and metastatic colorectal

    18/12/2022

    ISK is excited to report the official opening of its second FDA approved clinical trial in the US in patients with pancreatic cancer and metastatic colorectal cancer at Georgetown University in Washington, D.C.

  • ISK Ltd received FDA approval to start phase1/1b trial for treatment of GI tract mtKRAS tumors patients at Georgetown University at Washington DC

    23/10/2022

    ISK Ltd received FDA approval to start phase1/1b trial for treatment of GI tract mtKRAS tumors patients at Georgetown University at Washington DC

  • Georgetown University at Washington DC has signed a contract with ISK to run a clinical trial with patients with mtKRAS tumors

    17/02/2022

    The prestigious medical center Georgetown University at Washington DC has sign a contract with ISK to run a clinical trial with patients with mtKRAS pancreas and colon cancers.

  • PHASE 1B/2A Clinical trial started

    13/04/2021
  • Cooperation with Harvard Medical School (MGH)

    27/10/2019

    ISK has signed an agreement for cooperation with Harvard Medical School for drug development to treat neurodegenerative diseases

  • Permalink Gallery

    Second FDA approved clinical trial in patients with pancreatic cancer and metastatic colorectal

  • Permalink Gallery

    ISK Ltd received FDA approval to start phase1/1b trial for treatment of GI tract mtKRAS tumors patients at Georgetown University at Washington DC

  • Permalink Gallery

    Georgetown University at Washington DC has signed a contract with ISK to run a clinical trial with patients with mtKRAS tumors

  • Usylvester
    Permalink Gallery

    PHASE 1B/2A Clinical trial started

  • Permalink Gallery

    Cooperation with Harvard Medical School (MGH)

Recent Posts

  • Second FDA approved clinical trial in patients with pancreatic cancer and metastatic colorectal
  • IRB approval to open the trial in Georgetown University for the treatment of mtKRAS tumors from GI track
  • New Nerofe Formulation for treatment of Stage 4 squamous cell lung cancer
  • New Nerofe Formulation for treatment of adenocarcinoma in the anus with metastasis in the peritoneum
  • ISK Ltd received FDA approval to start phase1/1b trial for treatment of GI tract mtKRAS tumors patients at Georgetown University at Washington DC

Tags

AML AML drug cancer Clinical Trial human trial MDS Nerofe phase II research Treatment

Categories

  • News
  • About
  • News & Events
  • Contact Us
  • Disclaimer
Immune System Key (ISK) Ltd. Hava'ad Haleumi 21, Jerusalem 91160, Israel Tel: +972-50-2597031/2
logo
Copyright © 2015 ISK Ltd.